Pasithea Therapeutics Corp KTTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Trading Information
- Previous Close Price
- $0.52
- Day Range
- $0.46–0.58
- 52-Week Range
- $0.28–2.06
- Bid/Ask
- $0.48 / $0.52
- Shares Outstanding
- 33.41M
- Market Cap
- $17.44M
- Volume/Avg
- 2M / 633,618
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
- Website
- https://www.pasithea.com
Valuation
Metric | KTTA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.35 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KTTA |
|---|---|
Quick Ratio | 24.85 |
Current Ratio | 26.25 |
Interest Coverage | — |
Quick Ratio
KTTA
Profitability
Metric | KTTA |
|---|---|
Return on Assets (Normalized) | −44.51% |
Return on Equity (Normalized) | −47.29% |
Return on Invested Capital (Normalized) | −50.19% |
Return on Assets
KTTA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|C$Z&J^$ | LOCK|Ml#< | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@&y&#J | LOCK|hPTdP | $99B | |||
| Moderna Inc MRNA | LOCK|b?xv^P | LOCK|xJ | $90B | |||
| argenx SE ADR ARGX | LOCK|^Ph!m< | LOCK|wD< | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Nyy@ly# | LOCK|c<K | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&Ycz$rN# | LOCK|zv<V | $31B | |||
| Incyte Corp INCY | LOCK|xYMK$>? | LOCK|dP? | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$j^z!h | LOCK|BNQ$ | $22B | |||
| BioNTech SE ADR BNTX | LOCK|d^B<&!Q | LOCK|d& | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|bp?&TP | LOCK|T& | $16B |